What is it about?
Severe SpA, predominantly HLA-B27 negative, with osteitis/enthesitis may occur under successful VDZ treatment for IBD, including in subjects with prior anti-TNF therapy for intestinal disease.
Featured Image
Why is it important?
As we anticipate increasing use of a4b7inhibition, awareness of this paradoxical reaction and specific pheno- type among rheumatologists and gastroenterologists alike can facilitate combined management decisions for effective treatment of IBD and SpA or enthesitis.
Read the Original
This page is a summary of: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease, Rheumatology, September 2018, Oxford University Press (OUP),
DOI: 10.1093/rheumatology/key267.
You can read the full text:
Contributors
The following have contributed to this page
